A study of haploidentical transplantation with post-transplant cyclophosphamide and prophylactic donor lymphocyte infusions.
Not Applicable
Completed
- Conditions
- AML,ALL,MDS,NHL,CML Neuroblastoma,Rhabdomyosarcoma,Ewing sarcoma
- Registration Number
- JPRN-UMIN000030767
- Lead Sponsor
- Department of Pediatrics, Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are positive for HBs antigen, HCV antibody, or HIV antibody. 2. Patients with active other malignancies. 3. Women who are pregnant, of childbearing potential, or lactating. 4. Patients who experienced serious hypersensitivity or anaphylaxis to cyclophosphamide. 5. patients who are not eligble for this study at the discretion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method treatment related mortality within 100days
- Secondary Outcome Measures
Name Time Method 1. overall survival, event free survival, relapse rate at 100 days 2. overall survival, event free survival, relapse rate at 1 year 3. neutrophilans platlet engraftment 4. engraftment failure 5. complete chimerism 6. acute GVHD 7. chronic GVHD 8. infectious event 9. grade 3-4 toxicity within 100 days